Tech Company Financing Transactions

Altea Therapeutics Funding Round

Altea Therapeutics, operating out of Atlanta, secured $30 million from Aperture Venture Partners, Domain Associates and KBC Securities.

Transaction Overview

Company Name
Altea Therapeutics
Announced On
7/27/2005
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors

Aperture Venture Partners (Lead Investor) (Paul Tierney)

Domain Associates

KBC Securities (Ruth Devenyns)

RockPort Capital

Venrock

Proceeds Purpose
Altea Therapeutics will use the proceeds to continue the clinical development of our lead products for pain management and diabetes control. These funds will also support the further development of processes for the fabrication of our commercial products.

Company Information

Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
387 Technology Cir. NW 100
Atlanta, GA 30313
USA
Phone
(404) 835-6310
Website
www.alteatherapeutics.com
Email Address
[email protected]
Overview
Altea Therapeutics is an emerging private pharmaceutical company focused on developing and commercializing a broad portfolio of pharmaceutical products based on a new class of advanced transdermal patches that deliver sustained therapeutic levels of proteins and water-soluble drugs in a convenient, painless and cost-effective manner.
Profile
Altea Therapeutics LinkedIn Company Profile
Social Media
Altea Therapeutics Company Twitter Account
Company News
Altea Therapeutics News
Facebook
Altea Therapeutics on Facebook
YouTube
Altea Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Eric Tomlinson
  Eric Tomlinson LinkedIn Profile  Eric Tomlinson Twitter Account  Eric Tomlinson News  Eric Tomlinson on Facebook
VP - Bus. Development
Steven Damon
  Steven Damon LinkedIn Profile  Steven Damon Twitter Account  Steven Damon News  Steven Damon on Facebook
VP - Finance
Angela Walsh
  Angela Walsh LinkedIn Profile  Angela Walsh Twitter Account  Angela Walsh News  Angela Walsh on Facebook
VP - Product Management
Alan Smith
  Alan Smith LinkedIn Profile  Alan Smith Twitter Account  Alan Smith News  Alan Smith on Facebook
VP - R & D
Frank Tagliaferri
  Frank Tagliaferri LinkedIn Profile  Frank Tagliaferri Twitter Account  Frank Tagliaferri News  Frank Tagliaferri on Facebook
VP - Regulatory Affairs
Alexander Jacks
  Alexander Jacks LinkedIn Profile  Alexander Jacks Twitter Account  Alexander Jacks News  Alexander Jacks on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/26/2005: LightSand Communications venture capital transaction
Next: 7/28/2005: Alien Technology venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.